167 related articles for article (PubMed ID: 19930971)
1. Epigenetic modulation in hematologic malignancies: challenges and progress.
Mitsiades CS; Anderson KC
J Natl Compr Canc Netw; 2009 Nov; 7 Suppl 8():S1-12; quiz S14-6. PubMed ID: 19930971
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic manipulation of the immune response: a novel treatment strategy in hematologic malignancies.
Craddock C
Cytotherapy; 2011 May; 13(5):516-7. PubMed ID: 21375421
[No Abstract] [Full Text] [Related]
3. [Targeted epigenetic therapy of cancer. Achievements and perspectives].
Valdespino-Gómez VM; Valdespino-Castillo VE
Cir Cir; 2012; 80(5):470-80. PubMed ID: 23351455
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic therapies in haematological malignancies: searching for true targets.
Altucci L; Minucci S
Eur J Cancer; 2009 May; 45(7):1137-1145. PubMed ID: 19346125
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic therapy in hematological cancers.
Dimopoulos K; Grønbaek K
APMIS; 2019 May; 127(5):316-328. PubMed ID: 30859683
[TBL] [Abstract][Full Text] [Related]
6. The fundamental role of epigenetics in hematopoietic malignancies.
Galm O; Herman JG; Baylin SB
Blood Rev; 2006 Jan; 20(1):1-13. PubMed ID: 16426940
[TBL] [Abstract][Full Text] [Related]
7. Beyond genetics--the emerging role of epigenetic changes in hematopoietic malignancies.
Galm O; Esteller M
Int J Hematol; 2004 Aug; 80(2):120-7. PubMed ID: 15481439
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic therapy for solid tumors: from bench science to clinical trials.
Juo YY; Gong XJ; Mishra A; Cui X; Baylin SB; Azad NS; Ahuja N
Epigenomics; 2015; 7(2):215-35. PubMed ID: 25942532
[TBL] [Abstract][Full Text] [Related]
9. Role of epigenetic changes in hematological malignancies.
Lehmann U; Brakensiek K; Kreipe H
Ann Hematol; 2004 Mar; 83(3):137-52. PubMed ID: 15064862
[TBL] [Abstract][Full Text] [Related]
10. Alterations of DNA methylation in hematologic malignancies.
Rush LJ; Plass C
Cancer Lett; 2002 Nov; 185(1):1-12. PubMed ID: 12142073
[TBL] [Abstract][Full Text] [Related]
11. [A primer for epigenetics of hematological malignancies].
Nakajima H
Rinsho Ketsueki; 2016; 57(10):1835-1844. PubMed ID: 27725578
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylases and epigenetic therapies of hematological malignancies.
Mercurio C; Minucci S; Pelicci PG
Pharmacol Res; 2010 Jul; 62(1):18-34. PubMed ID: 20219679
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents.
Bishton M; Kenealy M; Johnstone R; Rasheed W; Prince HM
Expert Rev Anticancer Ther; 2007 Oct; 7(10):1439-49. PubMed ID: 17944568
[TBL] [Abstract][Full Text] [Related]
14. The clinical application of targeting cancer through histone acetylation and hypomethylation.
Gilbert J; Gore SD; Herman JG; Carducci MA
Clin Cancer Res; 2004 Jul; 10(14):4589-96. PubMed ID: 15269129
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
[TBL] [Abstract][Full Text] [Related]
16. Human DNA (cytosine-5)-methyltransferases: a functional and structural perspective for epigenetic cancer therapy.
Rondelet G; Wouters J
Biochimie; 2017 Aug; 139():137-147. PubMed ID: 28600135
[TBL] [Abstract][Full Text] [Related]
17. Remodeling epigenetic modifications at tumor suppressor gene promoters with bovine oocyte extract.
Wang Z; Yue Y; Han P; Sa R; Ren X; Wang J; Bai H; Yu H
Cytotherapy; 2013 Sep; 15(9):1164-73. PubMed ID: 23800731
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic therapy of cancer with histone deacetylase inhibitors.
Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibitors potentiate photodynamic therapy in colon cancer cells marked by chromatin-mediated epigenetic regulation of
Halaburková A; Jendželovský R; Kovaľ J; Herceg Z; Fedoročko P; Ghantous A
Clin Epigenetics; 2017; 9():62. PubMed ID: 28603560
[TBL] [Abstract][Full Text] [Related]
20. The potential role of epigenetic therapy in multiple myeloma.
Smith EM; Boyd K; Davies FE
Br J Haematol; 2010 Mar; 148(5):702-13. PubMed ID: 19912222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
